Sensei Biotherapeutics (NASDAQ:FTH) Stock Rating Reaffirmed as Buy by BTIG Research

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating restated by BTIG Research in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $55.00 target price on the stock. BTIG Research‘s price target would suggest a potential upside of 205.39% from the stock’s current price.

A number of other research firms have also weighed in on FTH. Needham & Company LLC started coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 price objective for the company. JonesTrading assumed coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a “buy” rating and a $55.00 price objective for the company. Guggenheim assumed coverage on Sensei Biotherapeutics in a research note on Wednesday, September 16th. They issued a “buy” rating and a $70.00 price objective for the company. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $51.00 price objective for the company. Finally, Lifesci Capital upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Trading Up 7.0%

Sensei Biotherapeutics stock traded up $1.18 during mid-day trading on Tuesday, hitting $18.01. The company’s stock had a trading volume of 147,964 shares, compared to its average volume of 248,404. The company has a market capitalization of $465.38 million, a PE ratio of -0.13 and a beta of -0.29. The company has a 50 day simple moving average of $29.91. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping the consensus estimate of ($5.04) by $2.20. Analysts expect that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

A number of institutional investors have recently made changes to their positions in FTH. Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics in the first quarter worth approximately $22,758,000. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics in the second quarter worth approximately $3,610,000. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics in the first quarter worth approximately $4,188,000. Bank of America Corp DE boosted its stake in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares during the last quarter. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.